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Abstract
Long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFA) have been 
proposed to have beneficial effect on cancer cachexia. The aims of the present 
study were to a) determine the incorporation of n-3 LCPUFA in erythrocytes 
(RBC) as a measurement of compliance to fish oil (FO)-supplement in lung 
cancer patients undergoing anti-neoplastic therapy; and b) evaluate the effect 
of the FO-supplement on weight-loss, mid arm muscle circumference, energy 
and protein intake, hand grip strength and quality of life. Forty-two patients with 
advanced lung cancer were randomized immediately after referral to ingest 
either 20 ml of FO or 20 ml of rapeseed oil (RO) daily. Patients were evaluated 
every three weeks. Twenty-five patients participated in the study for more than 
21 days. The RBC content in FO-group increased with 35%, 137% and 44%, 
respectively (p < 0.001, p < 0.001 and p < 0.001), but did not change in the RO-
group. Neither intention-to-treat analysis nor per-protocol-analysis revealed any 
statistically significant differences between the groups with respect to clinical 
outcomes.
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been achieved in studies with palliative pancreatic cancer patients, if 
patients are compliant to the treatment with fish-oil (FO) containing 
supplements [19]. 
For these reasons we wanted to test if supplements with n-3 
LCPUFA lead to incorporation of these fatty acids into the cell 
membranes during cytotoxic treatment and if that has beneficial 
effects on weight loss in patients with lung cancer. 
Materials and Methods
The investigation was approved by the regional ethical committee. 
Patients with small cell- or non-small cell lung cancer referred 
to the Clinic of Oncology, Rigshospitalet, Copenhagen, were eligible 
for the study. All patients received platinum-based chemotherapy 
(Carboplatin or Cisplatin) in combination with Vinorelbine or 
Etoposid. Patients were consecutively included disregarding previous 
weight loss. Patients were excluded, if they had ingested daily 
supplements of n-3 LCPUFA within 60 days prior to the time of 
randomization, suffered from spontaneous bleeding tendency or 
were in anti-coagulant therapy. Overall 44 patients were randomized 
by concealed allocation to receive either FO (N=21) or rapeseed oil 
(RO, N=23). However, one patient in the FO-group were excluded 
from the study before baseline due to clinical deterioration and 
one in the RO-group due to concomitant prostate cancer, leaving 
20 patients in the FO-group and 22 patients in the RO-group. The 
baseline characteristics of the included patient in the two groups are 
shown in Table 1. 
Patients were randomly assigned to the two treatment groups 
in a double-blinded way by sealed envelopes, and had their oils 
Abbreviations
ALA: Alpha-Linolenic Acid; DHA: Docosahexaenoic Acid; EPA: 
EicosaPentaenoic Acid; RBC: Erythrocyte; FO: Fish Oil; n-3 LCPUFA: 
Long-Chain n-3 Polyunsaturated Fatty Acids; RO: Rapeseed Oil; 
QoL: Quality of Life 
Introduction
Progressive nutritional deterioration with insufficient intake of 
macro- and micro-nutrients is common in cancer patients and is 
associated with changes in carbohydrate, lipid and protein metabolism 
[1,2]. Malnutrition occurs in 60% of all patients with small cell- and 
non-small cell lung cancer [2], and this is partly a consequence of 
cachexia, which is a multi-factorial syndrome including anorexia, 
severe weight loss, muscular atrophy and weakness [1,3,4,5]. 
Previous investigations have shown that cachexia deteriorates the 
patients quality of life (QoL) [6], shortens survival time, and reduces 
the response to chemotherapy [1,7,8,9]. Supplementations with 
energy and protein has not been proven efficient in inhibiting the 
deterioration [6,10,11], and the potential weight gain, if any, consists 
primarily of fat and water, and not lean body mass [6,11,12,13,14]. 
Cachexia is partly due to an increase in inflammatory cytokines, 
and as long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFA) 
have been shown to have anti-inflammatory and cytokine reducing 
effects [15], they may be beneficial in cancer patients with a high 
inflammatory response. n-3 LCPUFA has been shown to normalize 
some of the metabolic abnormalities in cachexia such as hyper-
metabolism and insulin-resistance in patients with pancreatic cancer 
[16,17,18]. Furthermore, good clinical results primarily on QoL have 
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delivered in dark bottles packed by the producer to contain either 
FO or RO. Patients were instructed to ingest a total of 20 ml of the 
given oil every day with their meals. Both oils supplied 681 kJ pr. 20 
ml. The FO was produced by FF-Denmark and contained 0.235 g of 
n-3 LCPUFA pr. ml (0.1 g/ml of eicosapentaenoic acid (EPA) and 
0.12 g/ml of docosahexaenoic acid (DHA)). The RO was supplied by 
Aarhus Karlshamn A/S and contained 0.078 g of ALA pr. ml and no 
n-3 LCPUFA. If disclosed by taste, patients were asked not to reveal 
the nature of the oil to the investigators. Total oil consumption was 
registered by daily records. Patients had to participate for at least 
21 days to allow for incorporation of n-3 LCPUFA into the cell 
membranes. 
The known side effects of FO are regurgitation, nausea and 
transient diarrhoea [20-25]. In case of suspected side effects of the 
oils, these were discontinued for three days to evaluate if they were 
responsible for the inconvenience. If a subject experienced serious 
side effects that could be potentially attributed to the oils, the code was 
broken by the doctor in charge of the patient. Ten patients withdrew 
from the study because of side effects; diarrhea (2), vomiting (3), 
increased illness (5). Furthermore, seven subjects dropped out of the 
study before the minimum period of 21 days due to death (2), reason 
not specified (4) and loss of contact (1). The reasons for drop-out 
were evenly distributed among the two oil groups (Figure 1). 
All patients were blindly evaluated and interviewed by the same 
person at three-week intervals. Outcome measures at these clinical 
control visits were:
Weight: Muscular strength was measured by a dynanometer 
(Jamar, Sammons Prestons Inc). Mid-arm circumference was 
measured on the right arm. Energy and protein intake was estimated 
by two different techniques: initially by a three days dietary registration 
at home (two weekdays and one week-end-day), and after 12 days by 
24-hour dietary recall interview as patients were not able to perform 
any more registrations. A special designed photomap of portion sizes 
was used for quantification during the interviews.
Patients completed the European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 
and LC13, which is specific for lung cancer patients. The scores 
related to fatigue and overall health state was used to reflect the 
patient’s quality of life (QoL).
Five ml of blood was collected in ice-cold EDTA-conditioned 
tubes. The blood samples were centrifuged (2300 g for 5 min at 4 
°C) to isolate erythrocytes (RBC), which was washed three times 
in isotonic NaCl solution. Isolated RBC were reconstituted 1:1 in 
physiological saline with 1mM EDTA and 0,005% BHT and kept at 
-80ºC until they were analyzed. Lipids were extracted from RBC by 
the Folch procedure [26], Trans esterified by BF3 and the resulting 
fatty acid methyl esters were separated using a gas chromatography 
(Hewlett-Packard - HP6890 with a Supelco SP2380 capillary column 
(30 m, i.d. 0.25 mm, and film thickness of 0.2 mm)). The levels of 
the individual fatty acids are presented as percent of the total gas 
chromatogram area (area %, equivalent to percent of all fatty acids 
Fish oil group Rapeseed oil group p
Sex (male/female) 13 / 7 9 / 13 0.211
Ages (y) 64.5 (59.0-73.3) (20) 69 (60.5-71.3) (22) 0.801
Body weight (kg) 76.6 (64.3-84.1) (19) 69.5 (57.1-72.8) (22) 0.100
Height (m) 1.74 ±0.1 (18) 1.67 ±0.1 (20) 0.029
BMI (kg/m2) 24.9 (21.6-25.9) (17) 22.9 (21.6-27.6) (20) 0.855
Weight change during 3 month prior to inclusion (%). 0.0 (-4.2-0.0) (19) – 6.7 (-14.8- -2.1) (20) 0.032
Energy intake (MJ/d) 8.5 (6.6-10.2) (16) 6.8 (5.7-9.0) (20) 0.098
Protein intake (g/d) 75 (64-90) (16) 70 (57-86) (20) 0.484
QoL: Fatigue score 33.3 (16.7-50.5) (19) 44.4 (22.2-66.7) (22) 0.316
QoL: Global health score 66.7 (50-83.3) (19) 58.3 (50-77) (22) 0.812
MS (kg) 33.0 (21.8-38.8) (20) 22.5 (18.8-28.4) (22) 0.195
MaC (cm) 29.4 (27.8-32.6) (20) 28.2 (25.9-31.3) (22) 0.378
Table 1: Baseline characteristics of the patients with lung cancer referred to anti-neoplastic treatment in the two intervention groups.
Data are given as mean ± SD-value for normal distributed data (student t-test) and median (1. quartile - 3. quartile) for non-parametric data (Mann-Whitney). 
Abbrevations: BMI: Body Mass Index; QoL: Quality of Life measured by EORTC-C30 and LC13. Scores are sums in the main sections of the questionaires, MS: 










n= 20 n= 22 Baseline 
n= 12 
 
n= 13 Day 21 





n=3  n=3  
Randomized n=44 









vomiting (3), dead(1). 
Figure 1: CONSORT flow-chart of 44 patients with lung cancer randomized 
to supplementary treatment with either 20 ml/d of fish oil or rapeseed oil.
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from C14:0 to DHA). Successful blood sampling and RBC fatty acid 
analysis was obtained from 40 patients at baseline and only 25 patients 
at the end of the intervention. Compliance was evaluated blindly by 
comparing the patients` daily supplement consumption records with 
the measured n-3 LCPUFA levels in RBC.
All data were analyzed with Analyse-it® Standard statistical 
Software (Analyse-it Software Ltd. Leeds, United Kingdom) and 
significance was set to p < 0.05. Data for height and duration of 
participation were tested for normality using the Shapiro-Wilk 
normality test. Group comparisons were performed using Student 
t-test for normal distributed data, and results are given as mean ± SD. 
Nonparametric distributed data were analyzed using Mann-Whitney 
test for unpaired data and Wilcoxon test for paired data, and results 
are given as median (1. and 3. quartile). Chi-square test (χ2- test) or 
Fishers exact test were used for binary data and the Spearman’s rank 
test for correlation.
Results and Discussion
Patients in RO-group had prior to inclusion lost significantly 
more weight than patients in FO-group (Table 1). This is a kind 
of “bad luck randomization”, and as no significant weight loss was 
observed in either group after the intervention, on could speculate if 
the rape-seed oil did better that the fish oil, as a progressive weight-
loss was stopped. However, the information about weight-loss 
prior to the entrance in the study was given by the patient and not 
calculated by measurements, and we know that weight is varying 
due chemotherapy due to edema. As a consequence we do not find it 
justified to conclude anything about the influence on the oils on the 
weight changes. According to the supplement consumption records, 
the patients in the FO-group consumed an average of 17.2 (12.9-18.0) 
ml oil pr. day for an average period of 48 days, whereas those in the 
RO-group ingested an average of 15.9 (11.6-18.0) ml/d in an average 
period of 49 days (p= NS). RBC fatty acid analysis was performed 
at baseline in 19 patients in the FO- and in 21 patients in RO-group 
and revealed no significant difference between the two groups (Table 
2). Similarly, there was no difference in the intervention periods in 
the patients showing up for blood samples (Table 2). Twenty-five 
patients (60%) were available for analysis after the intervention. 
Drop-out rates were the same in the two groups. The reasons were 
also similar, and it is doubtful whether the reasons for drop-out 
had anything to do with the oils. At the same time as the patients 
started the oil treatment, they also started chemotherapy, so we are 
reluctant to relate the symptoms to the oil treatment. About 1/3 of 
the patients dropped out because of rapid worsening of the disease 
or death. FO supplementation augmented n-3 LCPUFA and EPA in 
RBC significant more than RO supplement (Table 2). RBC-EPA was 
most pronouncedly affected by the FO supplement and increased by 
an average of 137 %. As shown in Figure 2, the relative increase in the 
EPA content of the RBC was closely associated with duration of the 
supplementation period. 
FO supplementation had no effect on weight-loss when 
analyzing the data as intention to treat or per pre-protocol (Table 
3). Furthermore, no significant correlations were observed between 
EPA-RBC-incorporation and changes in any of the clinical outcomes 
(data not shown). 
Contrary to most studies, the FO was administered relatively 
early in the course of disease with the objective to prevent weight loss. 
However, because of the high dropout rate, it is difficult to conclude 
with certainty whether or not the n-3 LCPUFA supplement may 
Before n=19 After n=21
Fatty acids in RBC Fish oil group Rapeseed oil group p value Fish oil group Rapeseed oil group p value
SFA 40.1 ±1.3 39.8 ±2.1 0.652 NS 38.7 ±2.0 38.6 ±2.3 0.917 NS
MUFA 20.0 ±1.5 20.7 ±1.8 0.202 NS 19.1 ±1.9 20.2 ±1.7 0.070 NS
PUFA 37.6 ±2.4 37.5 ±3.1 0.894 NS 40.6 ±4.3 39.3 ±3.6 0.300 NS
n-6 PUFA 27.8 ±2.3 27.4 ±2.0 0.610 NS 27.5 ±3.6 28.3 ±2.4 0.388 NS
n-3 PUFA 9.8 ±2.2 10.1 ±2.7 0.771 NS 13.1 ±4.0 11.0 ±2.4 0.044
ALA 0.1 ±0.1 0.2 ±0.1 0.466 NS 0.1 ±0.1 0.2 ±0.1 0.035
EPA 0.8 ±0.3 0.9 ±0.4 0.116 NS 1.9 ±1.5 1.0 ±0.4 0.009
DHA 4.1 ±1.1 4.6 ±1.6 0.286 NS 5.9 ±1.9 5.1 ±1.4 0.156 NS
Table 2: Erythrocyte (RBC) fatty acid content before and after intervention with fish oil or rapeseed oil.
Data are expressed as % of fatty acids and given as mean ± SD. Group comparisons were performed by Student t-test. Abbrevations: SFA: Saturated Fatty Acids, 
MUFA: Mono Unsaturated Fatty Acids, PUFA: Poly Unsaturated Fatty Acids, ALA: α-Linolenic Acid, EPA: Eicosapentaenoic Acid, DHA: Docosahexaenoic Acid. The 
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Figure 2: Correlation between duration of intervention in days and total 
percent increase in EPA content in RBC, in the fish oil group. r=0.77, p=0.001 
(n=14 due to missing data).
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have had a clinically relevant effect. Within this field there has been 
a general focus on EPA as the main anti-cachectic agent in fish oil 
[19]. However, the role of DHA separated from EPA has not been 
clearly ascertained as most trials have supplies both fatty acids in 
combination [27]. One should refrain from concluding that DHA 
possesses no anti-cachectic features, as DHA has been shown to 
suppress some of the same pro-cachectic agents as EPA [28].
The FO-supplement gave rise to a significant increase in RBC n-3 
LCPUFA, most pronouncedly in EPA, which correlated significantly 
with the duration of the FO-supplementation period. The effects 
of FO on RBC fatty acid composition in these cancer patients were 
comparable to the changes that was observed in two previous trials 
with healthy subjects [29,30].
Based on the self-reported consumption records, the subjects in 
the FO-group consumed approximately 17 ml of fish oil per day of 
the intended 20 ml/d and compliance in this study was thus actually 
superior to some of the previous trials in cancer patients [31,32]. The 
ingested dose of FO supplied on average 4.0 g/d n-3 LCPUFA (1.7 g 
EPA and 2.0 g DHA), which is within the range of doses recommended 
in a recent systematic review [33]. Others have suggested a minimum 
of 2 g/d of EPA [34,35], as some studies with lower doses have failed 
to show any beneficial effects [31,32,35]. 
There was some variation in absolute increase in RBC EPA-
content observed within the individual subjects in the FO-group; one 
patient had an increase of a factor of five in just 27 days, whereas 
another patient only had an increase of a factor of three during 
a period 76 days. This could indicate differences in metabolism, 
interfering differences in diet, or differences in body composition, 
but is most likely due to differences in compliance. The difference in 
achieved tissue level emphasizes the importance of a measurement 
of the immediate effect on fatty acid composition in membranes. 
Many of the previous cancer trials has assessed compliance only by 
self-reported consumption records and some have examined the n-3 
LCPUFA content of plasma lipids [3,16,18,32,36,37]. The plasma n-3 
LCPUFA content can however only be considered as an indicator of 
fatty acids ingestion during a short period of time, whereas RBC fatty 
acid content reflects the intake over a period of weeks or months [38]. 
As RBC has a mean survival of about 120 days in healthy persons, it is 
expected, that steady state is achieved in the incorporation after four 
months. Our results indicated that determination of the content of 
n-3 LCPUFA in RBC would be a good choice to monitor compliance 
in cancer patients. The present study shows that n-3LCPUFA is 
incorporated in RBC in a time dependent manner. A minimal period 
of supplementation must therefore be expected before any beneficial 
effect can be expected, and this might explain why two large clinical 
interventions studies found no advantageous outcome on cancer 
cachexia of n-3 LCPUFA supplementation for two weeks [31,39].
Conclusion
A daily intake of 17 ml/d FO for an average of 48 days did 
increase RBC membranes levels of EPA and DHA in lung cancer 
patients to the same extent as in healthy subjects and that RBC fatty 
acid measurement can be used as an indicator of compliance during 
FO treatment. However, FO supplement did not affect weight loss 
in these patients. As this study included few patients and had a 
high dropout rate, it is difficult to conclude whether n-3 LCPUFA 
supplementation have clinically relevant effects on cachexia in lung 
cancer patients when administered early in the course of their disease. 
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